Hong Kong

AbbVie's Covid-19 antibody partner wraps $221M Hong Kong IPO
AbbVie's Covid-19 antibody partner wraps $221M Hong Kong IPO
Endpoints
AbbVie
Harbour BioMed
IPOs
Hong Kong
Flag link:
RemeGen grabs one of the world's largest ever biotech IPOs
RemeGen grabs one of the world's largest ever biotech IPOs
Fierce Biotech
RemeGen
IPOs
Hong Kong
Flag link:
JW Therapeutics hauls in $300M IPO just as liso-cel-inspired CAR-T nears the finish line in China
JW Therapeutics hauls in $300M IPO just as liso-cel-inspired CAR-T nears the finish line in China
Endpoints
JW Therapeutics
IPOs
CAR-T
liso-cel
China
Hong Kong
Juno Therapeutics
WuXi AppTec
Flag link:
RemeGen readies $514M IPO as HKEX adds jewel to the crown
RemeGen readies $514M IPO as HKEX adds jewel to the crown
Endpoints
IPOs
HKEX
RemeGen
Hong Kong
Flag link:
How hot is Hong Kong's biotech IPO market? Two biotechs just raised $800M total
How hot is Hong Kong's biotech IPO market? Two biotechs just raised $800M total
Endpoints
Hong Kong
IPOs
Everest Medicines
Genor Biopharma
Flag link:
Ex-Celgene exec steers his biotech startup to Hong Kong IPO as potential cancer drug launch looms
Ex-Celgene exec steers his biotech startup to Hong Kong IPO as potential cancer drug launch looms
Endpoints
Celgene
Antengene
IPOs
startups
Jay Mei
Hong Kong
Flag link:
Juno joint venture seeks IPO haul to bring CAR-Ts to China
Juno joint venture seeks IPO haul to bring CAR-Ts to China
Fierce Biotech
JW Therapeutics
Juno Therapeutics
WuXi AppTech
IPOs
Hong Kong
CAR-T
Flag link:
China's CRO powerhouse Tigermed to seek $1B IPO in Hong Kong — report
China's CRO powerhouse Tigermed to seek $1B IPO in Hong Kong — report
Endpoints
China
Hong Kong
Hangzhou Tigermed
CRO
biotech
IPOs
Flag link:
Ophthalmic drugs, cancer cell therapies attract $340M+ on two HKEX biotech debuts
Ophthalmic drugs, cancer cell therapies attract $340M+ on two HKEX biotech debuts
Endpoints
biotech
IPOs
HKEX
Hong Kong
Ocumension Therapeutics
Immunotech Biopharm
Flag link:
Pandemic fears force Chinese biotech to postpone Hong Kong IPO meetings — Bloomberg
Pandemic fears force Chinese biotech to postpone Hong Kong IPO meetings — Bloomberg
Endpoints
China
Hong Kong
IPOs
Wuhan Coronavirus
InnoCare Pharma
Flag link:
Tasly Biopharma pitches long-awaited IPO — will it trigger another $1B gold rush on HKEX?
Tasly Biopharma pitches long-awaited IPO — will it trigger another $1B gold rush on HKEX?
Endpoints
Tasly Biopharma
IPO
Hong Kong
HKEX
Flag link:
This Chinese pharma filed for an IPO last September. Seven months and a $283M investment later, they are back at the HKEX
This Chinese pharma filed for an IPO last September. Seven months and a $283M investment later, they are back at the HKEX
Endpoints
Hansoh Pharmaceutical
China
IPOs
Hong Kong
Flag link:
Chinese Immuno-Oncology Company to Raise $282 Million Via Hong Kong IPO
Chinese Immuno-Oncology Company to Raise $282 Million Via Hong Kong IPO
CP Wire
CStone Pharmaceuticals
IPOs
China
Hong Kong
immuno-oncology
Flag link:
WuXi AppTec prices Hong Kong offering in stormy market
WuXi AppTec prices Hong Kong offering in stormy market
BioCentury
China
Hong Kong
WuXi AppTec
Flag link:
Can a $1B IPO attract leery investors on HKEX? WuXi AppTec is set to find out
Can a $1B IPO attract leery investors on HKEX? WuXi AppTec is set to find out
Endpoints
IPOs
Hong Kong
WuXi AppTec
Flag link:
Roche ties up again with Ascletis — this time on a commercial partnership for hep B drug
Roche ties up again with Ascletis — this time on a commercial partnership for hep B drug
Endpoints
Roche
hepatitis B
China
Hong Kong
Ascletis
Pegasys
Flag link:
Hong Kong IPO delivers $421M to Innovent — fourth listed biotech in six months
Hong Kong IPO delivers $421M to Innovent — fourth listed biotech in six months
Endpoints
Hong Kong
IPOs
biotech
Innovent Biologics
Flag link:
Innovent Biologics Plans Hong Kong IPO to Raise $423 Million, Despite Global Downturn
Innovent Biologics Plans Hong Kong IPO to Raise $423 Million, Despite Global Downturn
Biopharma Dive
IPOs
Innovent Biologics
Hong Kong
Flag link:
Ascletis Pharma, Asia’s first pre-profit listed biotech, plunges in Hong Kong three days after debut
Ascletis Pharma, Asia’s first pre-profit listed biotech, plunges in Hong Kong three days after debut
South China Morning Post
Asia
Hong Kong
Ascletis
Flag link:
Hong Kong could become biotech listing hub, says BeiGene boss as Chinese drug maker gears up for US$1 billion flotation
Hong Kong could become biotech listing hub, says BeiGene boss as Chinese drug maker gears up for US$1 billion flotation
South China Morning Post
Hong Kong
BeiGene
China
biotech
Flag link:

Pages